Home/Biosimilar Atlas/Trastuzumab/Reliance Life Sciences trastuzumab

Reliance Life Sciences trastuzumab

Trastuzumab biosimilar developed by Reliance Life Sciences. Reference product Herceptin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOJun 2015permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
TrastuzumabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer6rival developers in its markets

About Reliance Life Sciences trastuzumab

Reliance Life Sciences received its trastuzumab permission in India in June 2015, for both early and advanced breast cancer. It was the second Indian company to make trastuzumab after Biocon. The Indian regulator records the firm rather than the brand, so the product is listed under the company's name.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Jun 2015
Application or permission
MF-120/2015; BULK-119/2015
Indications as licensed
Adjuvant and metastatic breast cancer
Presentations
150 mg and 440 mg vials
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences trastuzumab holds an approval, these are the other trastuzumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO6Biocad (Biocad trastuzumab), Biocon Biologics (Ogivri / CANMAb), CuraTeQ Biologics (Dazublys / CuraTeQ trastuzumab), Dr. Reddy's Laboratories (Dr. Reddy's trastuzumab), Intas Pharmaceuticals (Intas trastuzumab), Zydus Lifesciences (Zydus trastuzumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, UstekiRel.

Chronology

Sources

All trastuzumab biosimilars

Planning trastuzumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.